CD5 and diffuse large B-cell lymphoma: CD5+ DLBCL is prone to elderly onset, advanced stage at diagnosis, and elevated LDH level, and the 5-year OS is less than 40% in the era of rituximab-based immunochemotherapy (30, 31).